PMID- 36905740
OWN - NLM
STAT- MEDLINE
DCOM- 20230418
LR  - 20230418
IS  - 1873-3557 (Electronic)
IS  - 1386-1425 (Linking)
VI  - 295
DP  - 2023 Jul 5
TI  - Spectroscopic, calorimetric and cytotoxicity studies on the combined binding of 
      daunorubicin and acridine orange to a DNA tetrahedron.
PG  - 122583
LID - S1386-1425(23)00268-8 [pii]
LID - 10.1016/j.saa.2023.122583 [doi]
AB  - Chemotherapy-phototherapy (CTPT) combination drugs co-loaded by targeted DNA 
      nanostructures can achieve controlled drug delivery, reduce toxic side effects 
      and overcome multidrug resistance. Herein, we constructed and characterized a DNA 
      tetrahedral nanostructure (MUC1-TD) linked with the targeting aptamer MUC1. The 
      interaction of daunorubicin (DAU)/acridine orange (AO) alone and in combination 
      with MUC1-TD and the influence of the interaction on the cytotoxicity of the 
      drugs were evaluated. Potassium ferrocyanide quenching analysis and DNA melting 
      temperature assays were used to demonstrate the intercalative binding of DAU/AO 
      to MUC1-TD. The interactions of DAU and/or AO with MUC1-TD were analyzed by 
      fluorescence spectroscopy and differential scanning calorimetry. The number of 
      binding sites, binding constant, entropy and enthalpy changes of the binding 
      process were obtained. The binding strength and binding sites of DAU were higher 
      than those of AO. The presence of AO in the ternary system weakened the binding 
      of DAU to MUC1-TD. In vitro cytotoxicity studies demonstrated that the loading of 
      MUC1-TD augmented the inhibitory effects of DAU and AO and the synergistic 
      cytotoxic effects of DAU + AO on MCF-7 cells and MCF-7/ADR cells. Cell uptake 
      studies showed that the loading of MUC1-TD was beneficial in promoting the 
      apoptosis of MCF-7/ADR cells due to its enhanced targeting to the nucleus. This 
      study has important guiding significance for the combined application of DAU and 
      AO co-loaded by DNA nanostructures to overcome multidrug resistance.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Zhang, Xinpeng
AU  - Zhang X
AD  - Institute of Biopharmaceutical Research, Liaocheng University, Hunan Road, 
      Liaocheng 252059, China. Electronic address: z954004605@163.com.
FAU - Li, Xinyu
AU  - Li X
AD  - School of Chemistry and Chemical Engineering, Liaocheng University, Hunan Road, 
      Liaocheng 252059, China. Electronic address: Lixinyu3564@163.com.
FAU - Wang, Danfeng
AU  - Wang D
AD  - Institute of Biopharmaceutical Research, Liaocheng University, Hunan Road, 
      Liaocheng 252059, China. Electronic address: 17865814851@163.com.
FAU - Weng, Tianxin
AU  - Weng T
AD  - Institute of Biopharmaceutical Research, Liaocheng University, Hunan Road, 
      Liaocheng 252059, China. Electronic address: tianxinweng2020@126.com.
FAU - Wang, Lu
AU  - Wang L
AD  - School of Chemistry and Chemical Engineering, Liaocheng University, Hunan Road, 
      Liaocheng 252059, China. Electronic address: 17863526817@163.com.
FAU - Yuan, Lixia
AU  - Yuan L
AD  - Institute of Biopharmaceutical Research, Liaocheng University, Hunan Road, 
      Liaocheng 252059, China. Electronic address: Yuan1072165059@163.com.
FAU - Wang, Qingpeng
AU  - Wang Q
AD  - Institute of Biopharmaceutical Research, Liaocheng University, Hunan Road, 
      Liaocheng 252059, China. Electronic address: lywqp@126.com.
FAU - Liu, Jie
AU  - Liu J
AD  - School of Chemistry and Chemical Engineering, Liaocheng University, Hunan Road, 
      Liaocheng 252059, China. Electronic address: liujielcu@126.com.
FAU - Wu, Yushu
AU  - Wu Y
AD  - Institute of Biopharmaceutical Research, Liaocheng University, Hunan Road, 
      Liaocheng 252059, China. Electronic address: yushuwu@126.com.
FAU - Liu, Min
AU  - Liu M
AD  - Institute of Biopharmaceutical Research, Liaocheng University, Hunan Road, 
      Liaocheng 252059, China; School of Chemistry and Chemical Engineering, Liaocheng 
      University, Hunan Road, Liaocheng 252059, China. Electronic address: 
      panpanliumin@163.com.
LA  - eng
PT  - Journal Article
DEP - 20230306
PL  - England
TA  - Spectrochim Acta A Mol Biomol Spectrosc
JT  - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
JID - 9602533
RN  - ZS7284E0ZP (Daunorubicin)
RN  - F30N4O6XVV (Acridine Orange)
RN  - 0 (Antineoplastic Agents)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - *Daunorubicin/pharmacology/chemistry
MH  - Acridine Orange
MH  - *Antineoplastic Agents/pharmacology
MH  - Drug Delivery Systems
MH  - DNA/genetics
OTO - NOTNLM
OT  - Binding affinity
OT  - Calorimetry
OT  - Combined drugs
OT  - Cytotoxicity
OT  - DNA nanostructures
OT  - Spectroscopy
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/03/12 06:00
MHDA- 2023/04/18 10:16
CRDT- 2023/03/11 18:06
PHST- 2022/12/06 00:00 [received]
PHST- 2023/02/23 00:00 [revised]
PHST- 2023/03/01 00:00 [accepted]
PHST- 2023/04/18 10:16 [medline]
PHST- 2023/03/12 06:00 [pubmed]
PHST- 2023/03/11 18:06 [entrez]
AID - S1386-1425(23)00268-8 [pii]
AID - 10.1016/j.saa.2023.122583 [doi]
PST - ppublish
SO  - Spectrochim Acta A Mol Biomol Spectrosc. 2023 Jul 5;295:122583. doi: 
      10.1016/j.saa.2023.122583. Epub 2023 Mar 6.